Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Results enable initiation of additional hypertension studies for lead candidateCompany to conduct a U.S. Phase II trial in targeted patient population based on FDA advice PARIS and NEW YORK, Sept. ...
-
PARIS and NEW YORK, Sept. 22, 2016 (GLOBE NEWSWIRE) -- Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet...
-
PARIS and NEW YORK, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet...
-
CEO Lionel Ségard to discuss clinical updates and latest company developments PARIS and NEW YORK, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Quantum Genomics (Alternext - FR0011648971 - ALQGC), a...
-
PARIS & NEW YORK, May 17, 2016 (GLOBE NEWSWIRE) -- Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company developing new therapies for unmet medical needs in the...
-
PARIS and NEW YORK, March 24, 2016 (GLOBE NEWSWIRE) -- Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company focused on the development of new therapies for unmet...
-
Establishes U.S. Clinical Advisory BoardAnnounces Plans to Open U.S. Office PARIS, France, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Quantum Genomics (Alternext - FR0011648971 - ALQGC), a...